4 / 5 Stars
Zacks Investment Research
1 (Strong Buy)
Standard & Poor's
U.S. News evaluated 34 Health Funds. Our list highlights the top-rated funds for long-term investors based on the ratings of leading fund industry researchers.
The fund has returned 45.71 percent over the past year, 30.20 percent over the past three years, 25.05 percent over the past five years, and 14.68 percent over the past decade.
|Trailing Returns||Updated 10.31.2013|
|Year to date||41.1%|
|3 Years (Annualized)||30.2%|
|5 Years (Annualized)||25.0%|
|10 Years (Annualized)||14.7%|
The investment seeks long-term capital growth. The fund normally invests at least 80% of net assets in the common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively termed "health sciences"). It can invest in companies of any size, the majority of fund assets are expected to be invested in large- and mid-cap companies. The fund may invest up to 35% of its total assets in foreign stocks, which include non-dollar denominated securities traded outside the U.S.
Fees are Low compared to funds in the same category.
VALIC Company I Health Sciences Fund has an expense ratio of 1.15 percent.
Risk is Above Average compared to funds in the same category according to Morningstar.